Stallergenes Greer : CA T1 2019 : croissance soutenue
>T1 19 : +11.2%, au-dessus de notre attente - Le CA T1 ressort à 84.7 M€ soit une hausse de +11.2% (+9% à tcc.) avec un CA Europe du Sud à 44.8 M€ (+11,2%), Europe du Nord à 12.4 M€ (+13.8%), USA, à 22.5 M€ (+6.6%) et les Autres zones progressent de +28.2%, portées par la Russie et l’Australie.Stallergenes-Greer confirme ses objectifs pour l’exercice 2019, communiqués le 21 mars dernier, à savoir un CA compris entre 290 et 300 M€, et un EBITDA compris entre 50 et...Stallergenes Greer is engaged in providing a comprehensive approach to allergies diseases, offering allergy specialists a range of products from diagnosis to sublingual and subcutaneous allergen immunothreaphy medicines. Co. portfolio comprises of four product categories; Sublingual products include ORALAIR® and STALORAL®; Subcutaneous products include ALUSTAL®, PHOSTAL®, ALYOSTAL ® and ALBEY®, and GREER EXTRACTS®; Veteninary product is a range of USDA-approved bulk extracts for animals suffering from a range of allergies; and Other products offer a variety of diagnostic tools and source materials in useful formulations for allergy specialists and physicians.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.